Women's Health

A NEW NON-HORMONAL CHOICE FOR HOT FLASHES: NICE APPROVES NK3 RAS FOR NHS USE.

Apr 11, 2026

•

6 min read

A NEW NON-HORMONAL CHOICE FOR HOT FLASHES: NICE APPROVES NK3 RAS FOR NHS USE.

NICE has now recommended the first drug in a genuinely new class - Fezolinetant in TA1143. It’s an NK3 receptor antagonist. This treatment is for moderate to severe menopausal vasomotor symptoms when HRT isn’t suitable.

Women's Health

THE LARGEST HRT MORTALITY STUDY AND WHAT IT MEANS FOR UK PRIMARY CARE CLINICIANS

Apr 8, 2026

•

3 min read

THE LARGEST HRT MORTALITY STUDY AND WHAT IT MEANS FOR UK PRIMARY CARE CLINICIANS

No excess mortality after 14 years. No signal for cardiovascular or cancer deaths; plus a survival benefit in women after bilateral oophorectomy.

Cardio renal metabolic (CRM)

Menopause in Primary care: HRT safety, LDL lipids and new NICE guidance

Apr 8, 2026

•

8 min read

Menopause in Primary care: HRT safety, LDL lipids and new NICE guidance

From raised LDL to a new non-hormonal drug class and the largest HRT safety study to date, this week is all menopause in primary care.

Women's Health

The latest evidence (2025–2026) on the benefits and risks of Menopausal HRT

Mar 9, 2026

•

15 min read

The latest evidence (2025–2026) on the benefits and risks of Menopausal HRT

Individualized HRT offers substantial symptomatic relief with acceptable safety when used appropriately; however, ongoing research is needed to address persistent uncertainties about long-term outcomes across diverse populations and evolving therapeutic options.